FAQ

Eduardo M Rego

Suggest Changes
Martin S. Tallman46
David Grimwade43
Roberto Passetto Falcão42
Hervé Dombret41
Miguel A. Sanz40
43Roberto Passetto Falcão
30Antônio Roberto Lucena-Araújo
21Rafael H. Jacomo
19Martin S. Tallman
16Bárbara Amélia Santana-Lemos

Filter Results:

  • Full text PDF available (45)

Publication Year

1985
2018
  • This year (18)
  • Last 5 years (38)
  • Last 10 years (75)

Publication Type

Co-author

Journals and Conferences

Learn More
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
Despite the good response of stem cell transplant (SCT) in the treatment of multiple myeloma (MM), most patients relapse or do not achieve complete remission, suggesting that additional treatment is… (More)
Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.
It has been demonstrated that genomic alterations of cells in the hematopoietic microenvironment could induce myelodysplastic syndromes (MDS) with ineffective hematopoiesis and dysmorphic… (More)
Antibody-targeted horseradish peroxidase associated with indole-3-acetic acid induces apoptosis in vitro in hematological malignancies.
Indole-3-acetic acid (IAA), when oxidized by horseradish peroxidase (HRP), is transformed into cytotoxic molecules capable of inducing cell injury. The aim of this study was to test if, by targeting… (More)
The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia.
The use of all trans-retinoic acid (ATRA) is the basis of treatment of acute promyelocytic leukemia (APL) and represents the paradigm of differentiation therapy. In general, ATRA is well-tolerated… (More)